AMR Industry Alliance provides report on members' progress tackling superbugs

29 January 2018

A new report from the AMR Industry Alliance, a group of over 100 life sciences firms focused on tackling the public health threat of antimicrobial resistance (AMR), provides an update on the practical steps members have undertaken in this area.

The biennial progress report looks at the areas of research and science, access, appropriate use and the environment, and presents data on AMR-relevant products such as antibiotics and vaccines.

Chairman Thomas Cueni described it as “the first industry-wide grouping of this scale that has been set up to respond to the AMR emergency.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK